Gary Myer

Joe Basil

Steve Jensen

- Provectus Biopharmaceuticals announced that independent preclinical research demonstrated its product, **PV-10**, activates the body's natural **STING immune pathway**, leading to stronger antigen presentation and more robust T-cell responses.  **[315545_f53958dc9c024d3ba070e1230a5ca501_0]** 
- This novel mechanism suggests PV-10 could be a **safer, more efficacious, and differentiated alternative** to existing vaccine adjuvants, potentially helping individuals who do not respond to current vaccines.  **[315545_f53958dc9c024d3ba070e1230a5ca501_0]** **[315545_f53958dc9c024d3ba070e1230a5ca501_1]** 
- The company believes this research validates PV-10 as a platform immune enhancer, expanding its potential into multi-billion-dollar addressable markets such as **infectious disease and oncology vaccines**, and pandemic preparedness programs.  **[315545_f53958dc9c024d3ba070e1230a5ca501_1]** 
- The vaccine adjuvant market is projected to exceed **$2 billion annually by 2030**, with global vaccine sales expected to surpass **$70 billion by 2030**, and oncology vaccines projected to be over **$10 billion by 2032**.  **[315545_f53958dc9c024d3ba070e1230a5ca501_1]**

PROVECTUS BIOPHARMACEUTICALS (PVCT)